Cytokinetics, Inc. (CYTK)
Stock Price:
$16.39 USD
0.17 (1.05%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $16.50 +0.11 (0.67%) Oct 23, 6:23 PM
Key Info
| Market Cap |
1.16B |
| Revenue (ttm) |
18.69M |
| Net Income (ttm) |
-140.40M |
| Shares Out |
70.50M |
| EPS (ttm) |
-2.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$16.39 |
| Previous Close |
$16.22 |
| Change ($) |
0.17 |
| Change (%) |
1.05% |
| Day's Open |
16.20 |
| Day's Range |
15.90 - 16.54 |
| Day's Volume |
694,701 |
| 52-Week Range |
7.73 - 30.14 |
More Stats
| Market Cap |
1.16B |
| Enterprise Value |
1.08B |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
70.50M |
| Float |
65.96M |
| EPS (basic) |
-2.35 |
| EPS (diluted) |
-2.37 |
| FCF / Share |
-1.70 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
8.78M |
| Short Ratio |
9.14 |
| Short % of Float |
13.31% |
| Beta |
1.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
61.84 |
| PB Ratio |
n/a |
| Revenue |
18.69M |
| Operating Income |
-110.35M |
| Net Income |
-140.40M |
| Free Cash Flow |
-101.11M |
| Net Cash |
75.02M |
| Net Cash / Share |
1.06 |
| Gross Margin |
-317.14% |
| Operating Margin |
-590.60% |
| Profit Margin |
-751.40% |
| FCF Margin |
-541.15% |
| ROA |
-32.03% |
| ROE |
-729.94% |
| ROIC |
-44.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$30.88*
(88.41% upside)
Low
24.0
Current: $16.39
High
43.0
Target: 30.88
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 26.87 | 31.50 | 13.37 | 106 | 28.66 | 46.94 | 30.65 | 7.56 | 4.00 | 2.58 |
| Revenue Growth | -14.71% | 135.64% | -87.44% | 271.3% | -38.95% | 53.16% | 305.45% | 88.98% | 55.22% | - |
| Gross Profit | 26.87 | 31.50 | 13.37 | 106 | 28.66 | 46.94 | 30.65 | 7.56 | 4.00 | 2.58 |
| Operating Income | -98.87 | -88.92 | -113 | 18.69 | -37.41 | -14.75 | -33.89 | -40.46 | -47.96 | -49.64 |
| Net Income | -122 | -106 | -128 | 16.45 | -37.50 | -14.65 | -33.72 | -40.37 | -47.86 | -49.29 |
| Shares Outstanding | 57.58 | 54.42 | 49.40 | 39.94 | 38.81 | 35.71 | 27.28 | 18.11 | 11.80 | 10.69 |
| Earnings Per Share | -2.11 | -1.95 | -2.59 | 0.39 | -0.97 | -0.41 | -1.24 | -2.30 | -4.30 | -4.62 |
| Operating Cash Flow | -90.91 | -101 | -102 | 36.98 | 4.88 | -44.84 | -7.72 | -33.44 | -45.60 | -44.83 |
| Capital Expenditures | -2.62 | -0.88 | -2.88 | -1.56 | -0.56 | -1.10 | -0.53 | -0.12 | -0.44 | -0.48 |
| Free Cash Flow | -93.53 | -102 | -105 | 35.42 | 4.32 | -45.95 | -8.25 | -33.56 | -46.04 | -45.31 |
| Cash & Equivalents | 225 | 199 | 269 | 156 | 111 | 83.23 | 77.73 | 74.00 | 49.22 | 72.43 |
| Total Debt | 136 | 43.18 | 31.78 | 29.88 | 14.64 | - | - | - | 0.15 | 0.99 |
| Net Cash / Debt | 89.04 | 156 | 237 | 126 | 96.80 | 83.23 | 77.73 | 74.00 | 49.07 | 71.44 |
| Assets | 290 | 211 | 295 | 170 | 115 | 133 | 83.19 | 77.55 | 52.77 | 77.99 |
| Liabilities | 301 | 185 | 185 | 75.78 | 46.65 | 40.90 | 28.75 | 7.47 | 4.60 | 7.48 |
| Book Value | -10.94 | 25.93 | 110 | 94.36 | 68.59 | 92.06 | 54.44 | 70.09 | 48.18 | 70.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cytokinetics, Inc. |
| Country |
United States |
| Employees |
156 |
| CEO |
Robert I. Blum |
Stock Information
| Ticker Symbol |
CYTK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CYTK |
| IPO Date |
April 29, 2004 |
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.